Amalgamated Bank Has $4.05 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Amalgamated Bank decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,319 shares of the medical equipment provider’s stock after selling 1,763 shares during the period. Amalgamated Bank’s holdings in Zimmer Biomet were worth $4,048,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $25,000. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet during the third quarter worth $28,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the third quarter worth $35,000. Finally, Kentucky Trust Co bought a new stake in Zimmer Biomet in the fourth quarter valued at $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of a number of research analyst reports. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $104.32 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The company’s 50-day moving average is $105.72 and its 200 day moving average is $107.38. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market capitalization of $20.77 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm posted $2.20 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.